Teva receives FDA approval for Prolia biosimilar [Yahoo! Finance]
Alvotech (ALVO)
Company Research
Source: Yahoo! Finance
a biosimilar to Prolia, alongside the acceptance of its biosimilar candidate applications for Xolair (omalizumab) by both the agency and the European Medicines Agency (EMA). The FDA approval of Ponlimsi is based on a comprehensive evidence package, including analytical and clinical data showing immunogenicity, safety, and similar efficacy to Prolia. Ponlimsi is approved for all indications of the reference product, such as treating postmenopausal women with osteoporosis at high risk of fracture and increasing bone mass in men with osteoporosis. Additional indications include glucocorticoid-induced osteoporosis in men and women at high fracture risk, increasing bone mass in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer, and in women undergoing adjuvant aromatase inhibitor therapy for breast cancer. The EMA granted marketing authorisation for Teva's Ponlimsi in November 2025, following a positive opinion from the Committee for Medicinal Products f
Show less
Read more
Impact Snapshot
Event Time:
ALVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALVO alerts
High impacting Alvotech news events
Weekly update
A roundup of the hottest topics
ALVO
News
- Alvotech (ALVO) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ALVO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "selMarketBeat
- Alvotech (ALVO) Revenue Surges 21% Year-Over-Year in 2025 [Yahoo! Finance]Yahoo! Finance
- Alvotech Files Annual Report with the SECGlobeNewswire
- Alvotech (ALVO) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ALVO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "hold"MarketBeat
- Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position [Yahoo! Finance]Yahoo! Finance
ALVO
Earnings
- 11/12/25 - Beat
ALVO
Sec Filings
- 3/31/26 - Form 20-F
- 3/19/26 - Form 6-K
- 3/12/26 - Form SCHEDULE
- ALVO's page on the SEC website